N6-methyladenosine-related long noncoding RNA is a potential biomarker for predicting pancreatic cancer prognosis

¹ Anhui Medical University, Clinical College of Peking University Shenzhen Hospital, Fifth Clinical Medical College of Anhui Medical University, China

² Peking University Shenzhen Hospital Clinical School, Futian District, Shenzhen, Guangdong Province, China

Tumor Discovery 2022, 1(2), 165 https://doi.org/10.36922/td.v1i2.165

Submitted: 4 August 2022 | Accepted: 23 September 2022 | Published: 11 October 2022

© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Pancreatic cancer is a common malignant tumor of the digestive system, with insidious onset, difficult early diagnosis, easy metastasis, and poor prognosis. N6-methyladenosine (m6A) and long non-coding RNA (lncRNA) play important roles in the prognostic value and immunotherapy response of pancreatic adenocarcinoma (PAAD). Therefore, it is crucial to recognize m6A-related-lncRNAs in PAAD patients. In this study, m6A-related lncRNAs were obtained by coexpression analysis. Univariate, the Least Absolute Shrinkage, and Selection Operator (LASSO) and multivariate Cox regression analyses were performed to construct m6A-related lncRNA prognostic models. Kaplan–Meier analysis, principal component analysis, feature-rich annotation, and nomogram were used to analyze the accuracy of risk models. Potential drugs targeting this model are also discussed. A prognostic model based on m6A-related lncRNAs was constructed, potential drugs targeting this m6A-related lncRNAs feature were discovered, and the relationship with immunotherapy response was studied. Finally, a nomogram was established to predict survival in PAAD patients. This m6A-based lncRNAs risk prognostic model may be promising for clinical prediction of prognosis and immunotherapy response in PAAD patients.

Keywords

Bioinformatics

N6-methyladenosine

Long non-coding RNA

Pancreatic adenocarcinoma

Funding

No external funding was received for this work.

References

[1]

Yan Q, Ni C, Lin Y, et al., 2021, ELK1 enhances pancreatic cancer progression via LGMN and correlates with poor prognosis. Front Mol Biosci, 8: 764900. https://doi.org/10.3389/fmolb.2021.764900

[2]

Liu Y, Cheng L, Song X, et al., 2022, A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer. Math Biosci Eng, 19(1): 191–208. https://doi.org/10.3934/mbe.2022010

[3]

Pratt HG, Steinberger KJ, Mihalik NE, et al., 2021, Macrophage and neutrophil interactions in the pancreatic tumor microenvironment drive the pathogenesis of pancreatic cancer. Cancers (Basel), 14(1): 194. https://doi.org/10.3390/cancers14010194

[4]

Luu TT, 2021, Review of immunohistochemistry biomarkers in pancreatic cancer diagnosis. Front Oncol, 11: 799025. https://doi.org/10.3389/fonc.2021.799025

[5]

Yang Y, Hsu PJ, Chen YS, et al., 2018, Dynamic transcriptomic m6A decoration: Writers, erasers, readers and functions in RNA metabolism. Cell Res, 28(6): 616–624. https://doi.org/10.1038/s41422-018-0040-8

[6]

Choe J, Lin S, Zhang W, et al., 2018, mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature, 561(7724): 556–560. https://doi.org/10.1038/s41586-018-0538-8

[7]

Roundtree IA, Luo GZ, Zhang Z, et al., 2017, YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife, 6: e31311.

[8]

Shi H, Wang X, Lu Z, et al., 2017, YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res, 27(3): 315–328. https://doi.org/10.1038/cr.2017.15

[9]

Zhou M, Zhao H, Xu W, et al., 2017, Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer, 16(1): 16. https://doi.org/10.1186/s12943-017-0580-4

[10]

Zhou M, Xu W, Yue X, et al., 2016, Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. Oncotarget, 7(20): 29720–29738. https://doi.org/10.18632/oncotarget.8825

[11]

Zhou KI, Parisien M, Dai Q, et al., 2016, N(6)- methyladenosine modification in a long noncoding RNA hairpin predisposes its conformation to protein binding. J Mol Biol, 428(5): 822–833. https://doi.org/10.1016/j.jmb.2015.08.021

[12]

Cai H, An Y, Chen X, et al., 2016, Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of insulin-like growth factor 2. Oncotarget, 7(52): 86857– 86870. https://doi.org/10.18632/oncotarget.13490

[13]

Xia T, Wu X, Cao M, et al., 2019, The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Pathol Res Pract, 215(11): 152666. https://doi.org/10.1016/j.prp.2019.152666

[14]

Tang B, Yang Y, Kang M, et al., 2020, m(6)A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer, 19(1): 3. https://doi.org/10.1186/s12943-019-1128-6

[15]

He Y, Hu H, Wang Y, et al., 2018, ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 methylation. Cell Physiol Biochem, 48(2): 838–846. https://doi.org/10.1159/000491915

[16]

Tu Z, Wu L, Wang P, et al., 2020, N6-Methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front Cell Dev Biol, 8: 642. https://doi.org/10.3389/fcell.2020.00642

[17]

Cho SH, Ha M, Cho YH, et al., 2018, ALKBH5 gene is a novel biomarker that predicts the prognosis of pancreatic cancer: A retrospective multicohort study. Ann Hepatobiliary Pancreat Surg, 22(4): 305–309. https://doi.org/10.14701/ahbps.2018.22.4.305

[18]

Li F, Zhang P, Khalaf OI, 2021, The N6-methyladenosine- (m6A-) associated genes act as strong key biomarkers for the prognosis of pancreatic adenocarcinoma. Comput Math Methods Med, 2021: 8715823.

[19]

Wei R, Qi G, Zeng Z, et al., 2021, IMUP and GPRC5A: Two newly identified risk score indicators in pancreatic ductal adenocarcinoma. Cancer Cell Int, 21(1): 620. https://doi.org/10.1186/s12935-021-02324-w

[20]

Ponting CP, Oliver PL, Reik W, 2009, Evolution and functions of long noncoding RNAs. Cell, 136(4): 629–641. https://doi.org/10.1016/j.cell.2009.02.006

[21]

Loewen G, Jayawickramarajah J, Zhuo Y, et al., 2014, Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol, 7:90. https://doi.org/10.1186/s13045-014-0090-4

[22]

Ghafouri-Fard S, Shoorei H, Branicki W, et al., 2020, Non-coding RNA profile in lung cancer. Exp Mol Pathol, 114: 104411. https://doi.org/10.1016/j.yexmp.2020.104411

[23]

Dousset L, Poizeau F, Robert C, et al., 2021, Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy. JCO Precis Oncol, 5: PO.21.00084.https://doi.org/10.1200/PO.21.00084

[24]

Allgauer M, Budczies J, Christopoulos P, et al., 2018, Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res, 7(6): 703–715. https://doi.org/10.21037/tlcr.2018.08.14

[25]

Liu J, Geng R, Yang S, et al., 2021, Development and clinical validation of novel 8-gene prognostic signature associated with the proportion of regulatory T cells by weighted gene co-expression network analysis in uterine corpus endometrial carcinoma. Front Immunol, 12: 788431. https://doi.org/10.3389/fimmu.2021.788431

[26]

Mayer P, Gaida MM, 2021, The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist. Pathologe, 42(5): 524–529. https://doi.org/10.1007/s00292-021-00949-2

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no conflicts of interest.

Previous article in this issue

Next article in this issue

Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing